Convener and Organizer of Activities and Engagements Related to Processes, Surveillance, and Policy Development of Medical Products for Ongoing Public Health Activities, U01 Clinical Trial Not Allowed

Active
Yes
Status
Posted
Published Date
April 15th, 2024
Close Date
June 17th, 2024
Total Funding
$700,000.00
Award Ceiling
$700,000.00
Expected No. Awards
1
Opportunity No.
RFA-FD-24-036

Agency

Food and Drug Administration (HHS-FDA)

Eligible Applicants

Others

Funding Category

Food and Nutrition

Funding Instrument

Cooperative Agreement

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Summary

The Food and Drug Administration (FDA) has posted a grant opportunity titled "Convener and Organizer of Activities and Engagements Related to Processes, Surveillance, and Policy Development of Medical Products for Ongoing Public Health Activities, U01 Clinical Trial Not Allowed". This opportunity falls under the category of Food and Nutrition and is a Cooperative Agreement type of funding instrument. The grant does not require cost sharing or matching. The purpose of this grant is to solicit applications from neutral, independent institutions and organizations to support meetings and activities that bring together multiple stakeholders to explore, research, and address issues related to medical products, policy, and surveillance methods and systems. The grant will support the design, planning, execution, synthesis, summary, and communication of findings from these forums to a broad range of organizations and individuals. The grant has an award ceiling of $700,000 and an estimated total program funding of $700,000. It is expected that one award will be granted. The closing date for applications is June 17, 2024, and the archive date is July 17, 2024. The grant is open to various types of Higher Education Institutions, including Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISIs), as well as faith-based or community-based organizations and regional organizations. For more information and to apply for the grant, please visit the following link: RFA-FD-24-036 Funding Opportunity Announcement. If you have any questions, you can contact Terrin Brown at terrin.brown@fda.hhs.gov.

Description

The purpose of this Notice of Funding Opportunity (NOFO) is to solicit grant applications from neutral, independent institutions and/or organizations to support meetings (e.g., conferences, workgroups, roundtables) that convene a broad range of multiple stakeholders, including those with relevant expertise, to explore, research, and address issues related to medical products, policy, and surveillance methods and systems. Support includes, but is not limited to the design, planning, execution, synthesis, summary, and communication of findings from these forums to a broad range of organizations and individuals.

Contact Information

Attachments
79 KB

Opportunity Lifecycle

Title
Type
Grant

Similar Opportunities

Clinical Studies of Orphan Products Addressing Unmet Needs of Rare Diseases (R01) Clinical Trials Required
Food and Drug Administration
The Food and Drug Administration (FDA) is offering a grant opportunity titled "Clinical Studies of Orphan Products Addressing Unmet Needs of Rare Diseases (R01) Clinical Trials Required". This grant aims to fund clinical trials of products that evaluate efficacy and/or safety in order to support a new indication or change in labeling to address unmet needs in rare diseases or conditions. The FDA expects that by funding collaborative, efficient, and/or innovative clinical trials, the number of approved treatments for rare diseases will increase, thereby having a positive impact on rare disease drug development. The grant does not require cost sharing or matching and falls under the category of Science and Technology and other Research and Development. The grant has a closing date of September 22, 2024, and the award ceiling is $650,000, with a minimum award floor of $200,000. It is expected that 20 awards will be granted. Eligible applicants include various types of organizations such as higher education institutions, nonprofits, for-profit organizations, governments, and foreign institutions. For more information, interested parties can visit the following website: [http://grants.nih.gov/grants/guide/rfa-files/RFA-FD-23-001.html](http://grants.nih.gov/grants/guide/rfa-files/RFA-FD-23-001.html). For any inquiries, the grantor contact is Shashi Malhotra, a Grants Management Specialist, who can be reached at shashi.malhotra@fda.hhs.gov or by phone at 2404027592.
FDA Support for Conferences and Scientific Meetings (R13 Clinical Trial Not Allowed)
Food and Drug Administration
The Food and Drug Administration (FDA) is offering a grant opportunity titled "FDA Support for Conferences and Scientific Meetings (R13 Clinical Trial Not Allowed)". This grant aims to provide federal financial assistance for high-quality conferences and scientific meetings aligned with the FDA's mission. The FDA recognizes the importance of supporting conferences and scientific meetings that contribute to public health. These events can include symposiums, seminars, workshops, or any formal meeting, whether conducted in person or virtually, to exchange information and explore subjects impacting public health within the scope of the FDA's mission. It is important to note that permission to submit a conference grant application does not guarantee funding at the requested level. The FDA will only issue a conference grant award if it can be issued before the start date of the conference. The grant has an estimated total program funding of $1,000,000 and expects to make 20 awards. The grant does not require cost sharing or matching. The eligibility for this grant is open to "Others", while foreign institutions are not eligible to apply. The close date for this grant is October 10, 2025, and more information can be found on the official website: [Full Announcement of PAR-23-072](https://grants.nih.gov/grants/guide/pa-files/PAR-23-072.html). For any inquiries, you can contact Janelle Fundersburg, the grantor, at janelle.fundersburg@fda.hhs.gov or by phone at 301-798-2533.
Drug Development Tools Research Grants (U01) Clinical Trials Optional
Food and Drug Administration
The Food and Drug Administration (FDA) is offering Drug Development Tools Research Grants (U01) through a Cooperative Agreement funding instrument. This opportunity falls under the category of Food and Nutrition and is currently open for applications. The grants aim to support the development of drug development tools that have an accepted or reviewable Letter of Intent (LOI) within the FDA's Drug Development Tool Qualification Program. These tools are intended to fill unmet needs in drug development and will be made publicly available once qualified. The grants do not require cost sharing or matching requirements. The estimated total program funding is $6 million, with an expected number of 6 awards to be granted. The award ceiling and floor are both set at $500,000. The closing date for applications is May 13, 2025, and the archive date is June 12, 2025. Eligible applicants include developers of drug development tools who have an accepted or reviewable LOI within the FDA's Drug Development Tool Qualification Program and are working towards their qualification plan or full qualification package. Previous recipients of DDT research grant support from FDA-CDER/CBER are also eligible to apply if they have successfully progressed to the next submission milestone and are requesting additional funding for new DDT project needs addressing different aspects of the project. For more information and to apply, please visit the following link: [RFA-FD-24-030 Funding Opportunity Announcement](https://grants.nih.gov/grants/guide/rfa-files/RFA-FD-24-030.html). If you have any questions, you can contact Terrin Brown, the grantor, at terrin.brown@fda.hhs.gov.